Replies to post #121772 on Biotech Values

[genisi]

It's interesting CBST is committed to start phase III for CXA201, but not CB-183,315.

I think CXA-201 is far more important for CBST. Anti Gram-negative infections drugs area is not as crowded as c. difficile infections and a much bigger one plus CBST is leading the pack especially for multi-drug resistant Gram-negative pathogens like pseudomonas aeruginosa, which is the most common one. In the c. difficile infections it is not clear if CB-183,315 will have an advantage in NAP-1 strains or have better reduction in recurrence rate than other CDAD products.